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Phase Separation of Intrinsically Disordered Protein 
Polymers Mechanically Stiffens Fibrin Clots
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Fibrin (Fb) networks self-assemble through the coagulation cascade and serve 
as the structural foundation of blood clots. Following severe trauma or drug 
therapy, reduced integrity of Fb networks can lead to formation of clots with 
inadequate mechanical properties. A key feature of therapeutic interventions 
for hemostasis is therefore the ability to restore mechanical strength to clots 
formed under coagulopathic conditions. Here, an intrinsically disordered 
protein based on an elastin-like polypeptide (ELP) sequence is described, 
which specifically binds Fb and modulates its mechanical properties. 
Hemostatic ELPs (hELPs) are designed containing N- and C-terminal peptide 
tags that are selectivity recognized by human transglutaminase factor XIIIa 
and covalently linked into fibrin networks via the natural coagulation cascade. 
Phase separation of hELPs above their lower critical solution temperature 
leads to stiffening and rescue of clot biophysical properties under simulated 
conditions of dilutive coagulopathy. In addition to phase-dependent 
stiffening, the resulting hELP-Fb networks exhibit resistance to plasmin 
degradation, reduced pore sizes, and accelerated gelation rate following 
initiation of clotting. These results demonstrate the ability of protein-based 
phase separation to modulate the physical and biochemical properties of 
blood clots and suggest protein phase separation as a new mechanism for 
achieving hemostasis in clinical settings.
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In cases of severe bleeding, clotting fac-
tors are rapidly depleted at the site of 
injury leading to a condition known as 
trauma-induced coagulopathy (TIC) in 
as many as 25% of trauma patients with 
an associated increase in mortality.[4,5] To 
date, there are few reports of intravenous 
hemostatic agents that can be infused sys-
temically to treat inaccessible or uncom-
pressible injury sites. Current standards 
of care involve transfusion of blood prod-
ucts such as frozen plasma or platelets, 
or the administration of clotting proteins, 
but these approaches are hampered by 
drawbacks such as high cost, short shelf 
life, limited efficacy, and special storage 
requirements.[6,7]
Hemostasis occurs in two phases, the 
primary phase of which involves activa-
tion and aggregation of circulating plate-
lets at the injury site, forming a platelet 
plug. In the secondary phase, fibrin (Fb) is 
polymerized, forming an insoluble protein 
hydrogel (i.e., clot) that provides structural 
support and hinders blood flow.[8] In this 
secondary phase, Fb networks form when 
activated thrombin cleaves fibrinopeptides from the precursor 
protein fibrinogen (Fg), revealing sequences known as knobs 
A and B. The knobs noncovalently bind to sites referred to as 
holes A and B on the distal ends of neighboring Fb/Fg, allowing 
Fb to self-associate in a half-staggered conformation and form 
protofibrils. These protofibrils then bundle together to form 
fibers and eventually an insoluble Fb network.[9,10] Fb networks 
are subsequently stabilized through covalent cross-links formed 
by a reaction between lysine and glutamine residues catalyzed 
by activated clotting-associated transglutaminase, factor XIIIa 
(FXIIIa).[11] Fb and FXIIIa are therefore both important players 
in hemostasis and represent valid molecular targets for hemo-
static control systems.
Targeting Fb with synthetic systems is challenging because of 
the difficulty in obtaining specific high-affinity binders that dis-
criminate between gelled Fb and circulating Fg. Since Fb clots 
and soluble Fg share sequence and structural homology, there 
are only a small number of conformational epitopes that can 
serve as a basis for molecular discrimination.[12] Nonetheless, 
phage display has been used successfully to isolate Fb-specific 
binders.[13,14] This has led to the development of Fb-targeting 
hemostats based on grafting Fb-binding peptides or nanobodies 
onto synthetic polymers or particles that bind Fb and support 
clot formation in vivo.[15–17]
1. Introduction
Severe trauma is a major cause of death among individuals 
45 years of age and younger, and is projected to account for 
as many as 8.4 million deaths per year in 2020. A plurality of 
these deaths are caused by failure to achieve hemostasis.[1–3] 
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Here, we present an alternative novel mechanism for spe-
cifically targeting Fb and supporting clot formation using phase 
separation of elastin-like polypeptides (ELPs). ELPs are intrinsi-
cally disordered protein polymers derived from the hydrophobic 
domain of the human extracellular matrix protein tropoelastin. 
ELPs comprise repetitive VPGXG pentapeptides, where X can 
be any amino acid excluding proline.[18] ELPs are widely used 
as drug delivery vehicles, components of hydrogels for tissue 
repair, monodisperse mechano-linkers in single-molecule 
experiments, and as components in protein purification and 
biomarker detection.[19–25] A key advantage of ELP-based mole-
cular systems over other natural and synthetic polymers is 
that they are produced by genetic engineering, and therefore 
precisely programmable at the DNA/amino acid level with no 
polydispersity.[21] ELPs are intrinsically disordered proteins and 
undergo stimuli-responsive phase separation into protein-rich 
coacervates at temperatures above their lower critical solution 
temperature (LCST). This process is driven by dehydration of 
the ELP,[26–28] and is tunable based on the length and composi-
tion of the ELP sequence.[29]
Evidence is emerging that phase separation is an important 
phenomenon in biology, commonly employed by cells to regu-
late RNA catalysis, modulate gene transcription, and control 
signaling.[30–32] In this context, ELPs are an ideal model system 
for studying and controlling molecular systems using phase 
separation. The phase transition of ELPs can modulate proper-
ties of synthetic materials, for example, controlling the optical 
density and mechanical strength of hybrid PEG hydrogels.[33,34] 
Recently, ELP phase separation was used for mRNA sequestra-
tion and gene expression control in artificial protocells.[35] ELP 
phase separation has also been used to modulate properties of 
ELP-hybrid hydrogels.[36] For example, Wang  et  al. described 
hyaluronic acid-bound ELPs which formed a secondary net-
work upon coacervation, thereby strengthening HA gels.[37]
Here, we designed and produced fibrin-binding hemo-
static ELPs (hELPs) by introducing glutamine and lysine resi-
dues at the N- and C-terminal ends of an ELP. Glutamine 
residues were embedded within a contextual sequence motif 
that was efficiently recognized by the clotting factor FXIIIa.[38] 
This design enabled enzyme-mediated covalent integration of 
hELP polymers into Fb networks catalyzed by FXIIIa. When 
introduced into Fb clots in vitro at physiological temperature, 
hELP-rich coacervates imparted significant enhancement in clot 
strength, resistance to perfusion, accelerated gelation following 
onset of clotting, and extended clot persistence in the presence 
of plasmin. HELPs lacking FXIIIa substrate tags or hELPs inte-
grated into Fb clots below their transition temperature did not 
show comparable improvements in mechanical strength, indi-
cating that both covalent integration and phase separation con-
tribute to enhancing clot stiffness. These results demonstrate 
the ability of hELPs to enhance biophysical properties of blood 
clots through added cross-linking and phase separation. We 
foresee that these materials can provide a synthetic alternative 
or supplement to current standards of care that are based on 
blood product transfusion, and therefore may avoid issues that 
are associated with using donor derived interventions.
2. Results and Discussion
2.1. Design and Characterization of Hemostatic ELPs (hELPs)
We designed hELPs with an ABC triblock architecture 
(Figure 1a). The repetitive ELP component present in all three 
Figure 1. Schematic representation of hELP design, and integration into Fb clots. a) hELPs were designed as triblock copolymers containing a Q-block, 
a phase separation block, and a K-block. b) Above the LCST, hELPs phase separate to form coacervates, which can be covalently cross-linked by FXIIIa. 
c) Upon mixing with fibrinogen, thrombin and FXIII, hELP coacervates covalently integrate into Fb networks and improve mechanical strength in a 
phase-dependent manner, and also improve the rate of clot development following the initiation of clotting, reduce the plasmin degradation rate, and 
reduce the Fb network pore size. Depictions of hELPs are schematic only, and may not reflect molecular structure.
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blocks comprised 11 VPGXG pentapeptides with alanine, valine, 
and glutamic acid residues in guest positions at a ratio of 2:8:1 
(A2V8E1). Coacervation of ELPs above their LCST is accompa-
nied by formation of ordered structures (e.g., β-spirals), and 
reduction in solvent accessible surface area.[29] The LCST of 
ELPs is influenced by a number of factors, including chain 
length, concentration, guest residue composition, and external 
factors such as ionic strength and pH.[39] Based on prior litera-
ture, we designed hELPs to have an LCST slightly below physi-
ological temperature so that coacervation was triggered when 
hELPs entered the physiological environment. In addition to the 
ELP component, the N-terminal hELP block, referred to as the 
Q-block, also contained four transglutaminase tags (Figure S1a, 
Supporting Information), each comprising a single glutamine 
residue embedded within a contextual sequence (DQMMLP-
WPAVAL). This contextual sequence was derived from prior 
work[38] which used phage display to identify a glutamine donor 
sequence that is recognized with high efficiency by FXIIIa. By 
embedding these glutamine donor sequences in the broader 
hELP sequence, we hypothesized that hELPs would selectively 
integrate into Fb networks at wound sites where FXIII is acti-
vated, while avoiding off-target interactions with soluble fibrin-
ogen.[40,41] We furthermore mutated a lysine residue within the 
contextual sequence to alanine (K11A), in order to eliminate 
the possibility of cross-links forming between Q-blocks. The 
middle phase separation block consisted of four consecutive 
A2V8E1 units, totaling 48 pentapeptide repeats. This block phys-
ically separated the Q- and K-blocks and extended the overall 
length of the hELP, thereby driving the LCST below physiolog-
ical temperature. The K-block followed the phase separation 
block at the C-terminus of hELPs and comprised four lysine-
donor sequences (GSKGS), which served as the complementary 
partner to glutamine in the reaction catalyzed by FXIIIa. A con-
trol ELP (conELP) was also prepared with the same sequence as 
hELP, except that glutamine and lysine residues were mutated 
to glycine such that conELP was not cross-linked by FXIIIa.
We cloned, expressed and purified hELPs and conELPs by 
inverse transition cycling (ITC), and measured LCSTs using a 
cloud point assay.[42] At a working concentration of 30 × 10−6 m, 
both hELP and conELP exhibited cloud points below 37 °C 
(32.7 and 34.1, °C respectively), indicating that both ELPs were 
aggregated at physiological temperature (Figure  2a). Next, we 
confirmed the functionality of the Q- and K-blocks by testing 
the ability of FXIIIa to cross-link hELP in the absence of 
Fg  using SDS-PAGE (Figure  2b). A reduction in intensity of 
the band corresponding to single hELP polymers (≈69.5 kDa), 
and the appearance of bands of higher molecular weights corre-
sponding to hELP dimers and multimers confirmed that FXIIIa 
was capable of cross-linking hELPs. Meanwhile, samples of 
conELP incubated with FXIIIa were not cross-linked. Molecular 
weights of hELPs and conELPs were confirmed by mass spec-
trometry (Figure S1, Supporting Information).
2.2. Integration of hELPs into Fb Networks
We N-terminally labeled hELPs and conELPs with Atto647-
N-hydroxysuccinimide (red channel) and confirmed they were 
still cross-linked by FXIIIa (Figure S2, Supporting Informa-
tion). Fluorescent-hELPs (f-hELPs) or fluorescent-conELPs 
(f-conELPs) were then integrated into Fb clots spiked with 1% 
AlexaFluor 488-labeled fibrinogen (Fg-488, green channel). 
We used two color confocal fluorescence microscopy to char-
acterize hELP and Fb network morphology, degree of hELP 
and Fb colocalization, and the influence of hELP phase transi-
tion on clot architecture. At 22 °C, all three clots (HEPES-Fb, 
conELP-Fb, and hELP-Fb) resulted in well-defined Fb networks 
when imaged in the green Fb channel (Figure 3a, left). When 
imaged in the red hELP channel, f-hELP fluorescence similarly 
showed an ordered network with high degree of spatial colocali-
zation between hELP and Fb signals (Figure 3a, left, hELP). We 
observed little to no fluorescence intensity in the red channel 
when only HEPES buffer or f-conELP were added during for-
mation of Fb networks (Figure 3a, left, HEPES and conELP).
To quantify hELP and Fb spatial colocalization, we used 
Coloc2 in ImageJ to calculate Pearson’s correlation coefficients 
(PCC).[43] For f-hELP-Fb clots at 22 °C, a PCC between f-hELP 
Figure 2. Cloud point and FXIIIa-mediated cross-linking of hELP and 
conELP. a) Cloud points were determined for 30 × 10−6 m solutions of 
hELP or conELP in 20/150 × 10−3 m HEPES/NaCl + 20 × 10−3 m CaCl2. 
Cloud points were defined as the temperature at which normalized trans-
mittance fell below 0.5. Data shown are mean ± SD (shaded area) (n = 2). 
b) SDS-PAGE gel following incubation of 50 × 10−6 m hELP or conELP with 
10 µg mL−1 human FXIIIa for 1 h at 37 °C. The arrow indicates the position 
corresponding to hELP dimers.
Adv. Funct. Mater. 2020, 30, 2005245
www.afm-journal.dewww.advancedsciencenews.com
2005245 (4 of 10) © 2020 The Authors. Published by Wiley-VCH GmbH
and Fb channels of 0.69 ± 0.1 indicated high spatial correlation. 
For f-conELP-Fb clots, a PCC value of 0.05 ± 0.09 indicated no 
spatial correlation (Figure  3b). These results demonstrate that 
when hELP is mixed with Fb and FXIIIa below the LCST, it is 
specifically cross-link and localizes to Fb fibers.
At 37 °C, above the hELP LCST (Figure 3a, right), the struc-
tures observed in conELP-Fb and hELP-Fb clots were consistent 
with the expected phase separation. Punctate spots of high 
ELP density indicated the formation of ELP-rich coacervates 
at T  > LCST. The density of ELP-rich coacervates was greater 
in f-hELP-Fb clots than in f-conELP-Fb clots due to conELPs 
lacking the Q and K residues required for covalent integra-
tion. F-hELP coacervates were not randomly distributed rela-
tive to the Fb network, exhibiting some colocalization with Fb 
Figure 3. Characterizing structural morphology of hELP-Fb clots. a) Two color confocal fluorescence microscopy of 1.5 mg mL−1 Fb clots formed at 22 
or 37 °C, with 30 × 10−6 m f-conELP, 30 × 10−6 m f-hELP or HEPES buffer as additives. Scale bars are 30 µm. b) Comparison of Pearson’s correlation 
coefficients quantifying spatial colocalization of signals from the Fb (green) or ELP (red) channels in confocal fluorescence images. c) Pore sizing 
of 1.5 mg mL−1 Fb clots containing 30 × 10−6 m hELP, 30 × 10−6 m conELP, or HEPES buffer. d) SEM images of 1.5 mg mL−1 Fb clots formed at 37 °C, 
with HEPES, 30 × 10−6 m conELP or 30 × 10−6 m hELP as additives. Images were taken at 20 000 and 70 000× magnifications. Statistical significance 
in panels (b) and (c) was determined using one-way analysis of variance (ANOVA) with Tukey’s post hoc test. *P <0.05 and ***P < 0.001. All data in 
panels (b) and (c) are shown as mean ± SD (n = 3).
Adv. Funct. Mater. 2020, 30, 2005245
www.afm-journal.dewww.advancedsciencenews.com
2005245 (5 of 10) © 2020 The Authors. Published by Wiley-VCH GmbH
fibrils. Image analysis of hELP-Fb clots at 37 °C yielded a PCC 
value of 0.163 ± 0.04. For f-conELP-Fb clots formed at 37 °C, we 
measured a PCC value of −0.04  ± 0.06, indicating no spatial 
correlation. The average diameter of hELP coacervates was 
determined from threshold images of three separate clots, and 
was found to be 0.73 ± 0.10 µm (Figure S3, Supporting Infor-
mation). The unimodal distribution of hELP coacervate sizes 
with a clear central peak suggests an energy balance that caps 
the growth of hELP coacervates inside Fb gels. Prior work on 
enzymatically cross-linked ELP hydrogels[44] or enzymatic inte-
gration of ELPs into collagen networks[45] has reported that 
enzyme-mediated cross-linking was not inhibited above the 
LCST. Our results are also consistent with these findings, and 
indicate that coacervation did not inhibit hELP association with 
Fb networks. In fact, multivalent hELP-rich coacervates with 
locally increased concentration of Q- and K-blocks may enhance 
FXIIIa-mediated cross-linking.
SEM images of 1.5 mg mL−1 Fb clots formed at 37 °C in the 
presence of 30 × 10−6 m ELP or HEPES buffer further highlight 
the structural effects hELPs have on Fb networks (Figure  3d). 
ConELP-Fb clots and HEPES-Fb clots both showed porous net-
works of thick fibers with relatively low degrees of branching. The 
addition of hELPs led to the formation of denser Fb networks, 
with thinner and more highly branched fibers. Furthermore, 
round aggregates bearing similarity to the coacervates observed 
in confocal microscopy were observed along the length of many 
of the fibers. The size of the putative ELP coacervates in the SEM 
images is significantly smaller than that determined from con-
focal microscopy images. We attributed this size difference to 
dehydration of the samples during SEM sample preparation.
FXIII is highly selective during the initial glutamine-binding 
step of the acyl transfer reaction, and less selective during the 
secondary step involving lysine recognition.[38] Typically FXIII 
cross-links Fb γ-chains into dimers, and α-chains into multimers. 
Cross-linking of γ-chains is known to occur more quickly, and 
involves γ406K on one chain linking to γ398/399Q of another 
chain.[41,46] Cross-linking of Fb α-chains by FXIII also occurs at 
multiple Q/K residue pairs.[41] Numerous Q- and K-residues on 
Fb γ-chains and α-chains are therefore the likely sites for hELP 
coacervate cross-linking through the Q- and K-blocks.
The potential for hELPs to be cross-linked by other transglu-
taminases does exist, however, the glutamine donor sequence 
used in the Q-block has high specificity for human FXIII, and 
low reactivity with another ubiquitous transglutaminase, TGase 
2.[38] Furthermore, FXIII is activated most effectively when 
bound to fibrin at wound sites, therefore the concentration of 
FXIIIa is highest at these sites, with minimal systemic concen-
tration found in the blood. Following FXIII activation and fibrin 
cross-linking, both FXIII and FXIIIa are broken down by pro-
teases released by polymorphonuclear granulocytes (PMNs), fur-
ther limiting their presence in blood.[41] Based on these factors, 
we expect that hELP cross-linking will be localized to wound 
sites in vivo, and that the potential for off-target interactions of 
hELPs following intravenous administration is minimal.
2.3. Quantification of Pore Sizes
Pore size is an important architectural feature that contributes 
to Fb clot stiffness and resistance to enzymatic degradation.[47] 
Covalent cross-linking of Fb fibrils by FXIIIa reduces pore 
size, while supplemental FXIIIa in vitro increases stiffness 
and resistance to fibrinolysis.[48,49] We investigated the effect of 
hELPs using a gravimetric perfusion assay where we measured 
liquid flow rates through hELP-Fb clots and then used Darcy’s 
law and a model developed by Carr and Hardin[47,50] to estimate 
pore size.
At 22 °C, the flow rates through HEPES-Fb and conELP-Fb 
control clots were ≈100× higher than the flow rates through 
hELP-Fb clots (Figure S4, Supporting Information). These flow 
rates translated into average pore radii of 686.6 ± 39.3, 761.2 ± 
41.8, and 73.6 ± 5.4 nm for HEPES-Fb, conELP-Fb, and hELP-
Fb clots, respectively (Figure  3c). The ≈10-fold smaller pore 
radius observed for hELP-Fb clots represented a significantly 
larger pore size reduction than previously reported for clots 
treated with either supplementary FXIII (a 2.1× reduction),[48] 
or synthetic fibrin-binding polymers (a 1.5× reduction).[47] SEM 
analysis of HEPES-Fb, conELP-Fb, and hELP-Fb under vacuum 
was also qualitatively consistent with pore size reduction 
(Figure 3d).
At 37 °C, pore radii in both HEPES-Fb and conELP-Fb con-
trol clots were smaller than at 22 °C (390.3 ± 28.9 and 504.3 ± 
51.3  nm, respectively), which we attributed to a temperature 
dependence of FXIIIa activity.[41] In hELP-Fb clots however, the 
pore radius at 37 °C was 124.8  ± 11.5  nm, slightly larger but 
not significantly different from the radius at 22 °C (Figure 3c). 
An increase in temperature from 22 to 37 °C therefore did not 
lead to a significant change in apparent pore size as measured 
by gravimetric perfusion for hELP-Fb clots, as was observed in 
the controls. This could indicate that hELP-Fb clots are already 
maximally cross-linked at 22 °C.
2.4. Gelation Kinetics
We investigated the effect of hELPs on gelation kinetics using a 
turbidity assay in a UV–vis spectrophotometer (Figure 4a). Prior 
work has shown that the gelation of Fb clots correlates with an 
increase in the turbidity of the clot.[47,51,52] In our experiment, 
absorbance values of gelling Fb clots were measured at 350 nm 
over a period of 1 h at 37 °C. Several distinct gelation profiles 
emerged across the different groups. HEPES-Fb clots showed a 
brief initial lag phase of gelation, followed by a gradual increase 
in absorbance over a period of ≈6 min, after which absorbance 
reached a plateau at 0.75  ± 0.12 AUs. ConELP-Fb clots had a 
similar initial lag phase, but this was followed by a more rapid 
increase in absorbance lasting approximately 45 s, after which 
a plateau was reached at 0.38  ± 0.07, which was significantly 
lower than the one seen in HEPES-Fb clots. The absorbance 
profile of hELP-Fb clots showed a lag phase and growth phase 
that were similar in length to the ones observed in conELP-Fb 
clots; however, hELP-Fb clots reached a significantly higher 
plateau absorbance of ≈0.9 ± 0.02.
We further measured gelation kinetics of 2.2  mg mL−1 Fb 
clots using low-strain oscillatory shear rheology under physi-
ological conditions, focusing in particular on the shear storage 
(G′) and loss (G″) moduli. HEPES-Fb and conELP-Fb clots, an 
initial lag phase, was followed by a period of rapid gelation and 
a secondary phase of slower asymptotic growth of G′ (Table 1; 
Figure S5, Supporting Information). The gelation time for 
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conELP-Fb and HEPES-Fb clots (defined as the point where 
G′ > G″) occurred at 390 and 330 s, respectively, while the gel 
point for hELP-Fb clots (with 30 × 10−6 m hELP) occurred signif-
icantly later at 540 s. In order to determine if steric hinderance 
of Fb clot formation was occurring due to high concentrations 
of hELP, we also performed the experiment on clots containing 
20, 10, and 5 × 10−6 m hELP, and found that the gel point 
occurred earlier than controls in Fb clots with 10 × 10−6 m hELP. 
Following onset of gelation, G′ of hELP-Fb clots increased more 
rapidly than in HEPES-Fb or conELP-Fb clot at all hELP con-
centrations, however this effect was most pronounced with the 
addition of 20 and 30 × 10−6 m hELP. In clinical hemostasis, 
Fg concentrations below ≈2.3 mg mL−1 are associated with 
increased mortality.[46,52] By defining the maximum G′ achieved 
by HEPES-Fb clots over 3600 s in this experiment as the crit-
ical threshold (specifically, 127.6  ± 18.1  Pa), we could quantify 
the time required for hELP-Fb clots to reach a stiffness signifi-
cantly greater than that of clots formed at this critical Fg con-
centration. Clots formed with 30 × 10−6 m hELP exceeded this 
threshold after 1860 s, clots formed with 20 × 10−6 m hELP did 
so after 1470 s, and clots formed with 10 × 10−6 m hELP did so 
after 2160 s. ConELP-Fb clots, and clots formed with 5 × 10−6 m 
hELP never significantly exceeded this threshold. The presence 
of hELP coacervates therefore had an inhibitory effect on time 
until initiation of clotting, but a positive effect on the subse-
quent rate of clot development.
2.5. Influence of hELPs in Thromboelastography
Thromboelastography (TEG) is a clinical technique for meas-
uring the clotting capacity of blood, which is based on the dis-
placement of a free-moving pin, submerged in a clotting blood 
sample within a rotating cup.[53] Here, we evaluated three TEG 
parameters, namely, reaction time (R), which measures the 
time to initiation of clot formation (i.e., the time until pin dis-
placement reaches 2 mm), α-angle which measures the rate of 
clot development after the R point has been reached, and max-
imum amplitude (MA) which measures clot stiffness in terms 
of the maximum displacement achieved by the pin over the 
Table 1. Gelation kinetics parameters from rheological measurements of 
2.2 mg mL−1 Fb clots forming at 37 °C.






HEPES 330 N/A 0.08
30 × 10−6 m conELP 390 N/A 0.13
5 × 10−6 m hELP 480 N/A 0.14
10 × 10−6 m hELP 300 2160 0.21
20 × 10−6 m hELP 690 1470 0.28
30 × 10−6 m hELP 540 1860 0.27
a)The time until G′ of sample exceeds the maximum G′ of the HEPES control.
Figure 4. Gelation kinetics of Fb clots in the presence of hELP or conELP. a) Absorbance of gelling 2.2 mg mL−1 Fb clots containing 30 × 10−6 m hELP, 
conELP, or HEPES buffer at 37 °C at 350 nm. Measurements were taken at 15 s intervals over a period of 1 h. b) Clotting onset time (R), c) α-angle, 
and d) maximum amplitude (MA) of Fb clots containing 30 × 10−6 m hELP, conELP, or HEPES buffer as measured by thromboelastography at 37 °C. 
Data in panels (b), (c), and (d) are shown as mean ± SD (n = 3). *P < 0.05, **P < 0.01, and ***P < 0.001; one-way ANOVA with Tukey’s post hoc test.
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course of the experiment. Here too a similar picture emerged 
of two phases of hELP-Fb clot formation as was observed in 
the turbidimetric and rheological experiments described above. 
The initiation of clotting required more time in hELP-Fb clots 
than in conELP-Fb or HEPES-Fb clots, at both low and high 
Fb concentrations (Figure  4b). However, following the onset 
of clotting, HELP-Fb clots containing 1.5  mg mL−1 Fb had a 
significantly higher α-angle (41.43  ± 2.15°) than HEPES-Fb or 
conELP-Fb controls, (27.83  ± 1.95° and 25.93  ± 3.26°, respec-
tively) (Figure  4c). When the Fb concentration was increased 
to 3.0 mg mL−1, the increase in α-angle for hELP-Fb clots rela-
tive to controls was more modest. In this case, hELP-Fb clots 
had an α-angle of 58.2 ± 1.6° while α-angles for HEPES-Fb and 
conELP-Fb clots were 47.9 ± 2.31° and 47.07 ± 4.04°, respectively. 
In previous studies, FXIII was found to be critical to the sec-
ondary phase of clot stiffening during gelation, and as hELPs 
are integrated into Fb clots by FXIII, it may be the case that 
their presence increases the rate of this secondary phase.[54] 
Therefore, while the initial onset of clotting takes longer 
in the presence of hELPs (as indicated by the increased R value), 
the subsequent rate of clot development is also increased; ulti-
mately, the efficacy of hELPs as hemostats will depend on the 
interplay of these two factors in vivo.
The effect of hELPs on MA values was similar to the one 
observed with the α-angle. For hELP-Fb clots containing 
30 × 10−6 m hELP and 1.5 mg mL−1 Fb, MA rose 62% and 59% 
relative to HEPES and conELP-containing clots, respectively. 
For hELP-Fb clots formed with 3.0 mg mL−1 Fb, MA was 16% 
higher than HEPES-Fb clots, and 24.5% higher than conELP-Fb 
clots (Figure  4d). Taken together, these TEG results indicated 
that hELPs had a more pronounced positive effect on clot prop-
erties for clots with lower, subcritical threshold concentrations 
of fibrin.
2.6. Effect of hELP Coacervates on Fb Clot Mechanics
We used oscillatory shear rheology to measure the effect of 
hELPs on clot stiffness (G′) with Fb concentrations above and 
below the critical Fb concentration threshold of 2.2  mg mL−1. 
At 22 °C, no significant differences in G′ were observed at any 
Fb concentration for HEPES-Fb, conELP-Fb or hELP-Fb clots 
(Figure 5a). At 37 °C, however, we found a significant increase 
in G′ across all Fb concentrations for hELP-Fb clots. HELP-Fb 
clots with the lowest Fb concentration (1.5 mg mL−1) exhibited 
G′ of 201.3 ± 16.4 Pa, which was significantly higher than those 
of conELP-Fb (71.0  ± 11.6  Pa) or HEPES-Fb (45.0  ± 12.8  Pa) 
clots. The G′ of hELP-Fb clots formed with 1.5 mg mL−1 Fb was 
Figure 5. In vitro characterization of mechanical properties of 
hELP-Fb clots. a) Average shear storage moduli of Fb clots containing 
either 30 × 10−6 m hELP, conELP, or an equivalent volume of HEPES 
buffer. Gels were allowed to form between the cone and plate of the 
rheometer at either 22 or 37 °C, after which a frequency sweep was 
performed from 0.1 to 3 Hz at 1% strain. The dotted line indicates the 
critical physiological threshold stiffness corresponding to the average 
shear storage modulus of the 2.2  mg mL−1 Fb HEPES control clot. 
b) Average shear storage moduli of 1.5–3.0 mg mL−1 Fb clots formed at 
37 °C with (5–30) × 10−6 m hELP as an additive. The dotted line indi-
cates the shear storage modulus of a 2.2 mg mL−1 Fb HEPES control clot. 
c) Strain sweeps from 0.1% to 100% (f = 1 Hz) of 2.2 mg mL−1 Fb gels 
containing 30 × 10−6 m hELP, conELP, or HEPES buffer at 37 °C. Data in 
all panels are shown as mean ± SD (n = 3)). *P < 0.05, **P < 0.01, and 
***P < 0.001; one-way ANOVA with Tukey’s post hoc test.
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equivalent to the G′ of control clots formed at a physiological Fb 
concentration of 2.2 mg mL−1. This indicated that at T > LCST, 
hELP coacervates restored clot stiffness to physiological values 
under simulated conditions of TIC and depleted Fg.[55]
The phase transition dependence of the stiffening effect of 
hELPs in Fb clots can be explained in several ways. First, the 
high local concentration of hELP molecules in the coacervate 
may promote the formation of more intermolecular hELP-
hELP cross-links, establishing a secondary network. In vivo, a 
similar effect is observed in the phase-separation-driven forma-
tion of biomolecular condensates, wherein local concentration 
enhancement of substrates and enzymes can accelerate chem-
ical reactions. This has been shown to increase rates of reaction 
in actin polymerization[56] and RNA catalysis, for example.[31] 
Secondly, aggregation of hELPs above their LCST may drive 
the formation of a secondary network of cross-links between Fb 
molecules, independent of the formation of inter-hELP cross-
links. The formation of secondary networks in hydrogels by 
thermal assembly of ELPs was also reported by Wang et al., who 
showed that the aggregation of hydrazide-modified ELPs cross-
linked into Hyaluronic Acid hydrogels resulted in a mechanical 
stiffening of those materials.[37] Finally, the phase separation of 
hELPs bound to Fb may exert mechanical forces on Fb fibers, 
creating a strain-stiffening effect even in the absence of external 
tension, recapitulating the active cell-driven contractile strain-
stiffening that occurs in fibrin networks having imbedded 
fibroblasts and platelets.[57] Strain stiffening is a well-known 
property of Fb networks and ELP coacervation is known to 
stiffen ELP hydrogels and exert mechanical forces.[58–60] There 
is evidence that the mechanical force of molecular aggregation 
is applied in other contexts in vivo: Shin et al. recently showed 
that the phase separation of intrinsically disordered proteins 
associated with chromatin functions to physically pull-together 
distal genomic elements, while mechanically excluding others, 
in a mechanism that controls DNA transcription.[61] However, 
given that the stiffening effect is observed for hELPs that are 
preheated/aggregated prior to Fb polymerization, active con-
traction/stiffening of the network by hELP coacervates may not 
be a major contributor to the stiffening of hELP-Fb clots.
Additionally, we investigated how different concentrations 
of hELP influence the mechanical stiffening of hELP-Fb clots. 
Frequency sweeps were performed at 37 °C as described above, 
with clots consisting of 1.5–3.0  mg mL−1 Fg, and 5 × 10−6, 
10  × 10−6, 20 × 10−6, or 30 × 10−6 m hELP (Figure  5b). When 
the concentration of Fg was below the critical threshold, only 
hELP at concentrations of 20 × 10−6 and 30 × 10−6 m were suf-
ficient to raise the mechanical strength of clots from subcritical 
to threshold levels. At Fg concentrations of 2.2  mg mL−1, all 
concentrations of hELP were able to raise the strength of clots 
above that of the HEPES control (G′  = 175.0  ± 15.5  Pa), how-
ever, the increase in stiffness was much larger for clots with 
20 × 10−6 or 30 × 10−6 m hELP (G′  = 416.9  ± 73.8 and 387.2  ± 
92.1 Pa, respectively), than for clots with 5 × 10−6 or 10 × 10−6 m 
hELP (G′  = 243.2  ± 50.4 and 233.4  ± 35.4  Pa, respectively). A 
similar pattern was observed at the highest concentration of Fg 
tested, where clots with 20 × 10−6 or 30 × 10−6 m hELP had shear 
storage moduli of 557.8  ± 13.9 and 616.9  ± 73.1, respectively, 
and clots formed with 5 × 10−6 or 10 × 10−6 m hELP had shear 
storage moduli of 388.2 ± 23.9 and 417.2 ± 56.1, respectively.
2.7. Influence of hELPs on Strain Stiffening of Fb Clots
Strain stiffening in Fb clots has been attributed to the mul-
tiscale structural organization of Fb networks, from single 
monomers, to protofibrils, to protofibril bundles, and fibers. 
According to this theory, as Fb networks are strained, force is 
first entropically dissipated by minimizing thermal fluctuations 
of flexible interfibril cross-links, and subsequently through the 
stretching of fibrils themselves. Eventually, at higher tension 
the secondary, tertiary, and quaternary structural elements of 
folded regions within Fb domains are denatured, giving rise to 
strain stiffening behavior that is uncommon in synthetic cross-
linked polymer networks.[62,63]
To determine what effect hELPs have on Fb strain stiffening, 
we performed oscillatory rheology using strain ramps from 
0.1% to 100% (Figure 5c). At low strains (0.1–1%), hELP-Fb clots 
containing 30 × 10−6 m hELP and 2.2 mg mL−1 Fb exhibited an 
increase in G′ as compared to conELP-Fb or HEPES-Fb clots, 
consistent with observations in the low amplitude frequency 
sweep experiments (Figure  5a). At medium (1–10%) and high 
strains (10–100%), all clots showed strain-stiffening behavior; 
however, the onset strain of the stiffening was higher for hELP-
Fb (≈10%) than for conELP-Fb or HEPES-Fb clots (≈2–3%). The 
rate of strain stiffening was higher in HEPES-Fb and conELP-
Fb clots than for hELP-Fb clots, as indicated by the maxima 
of the first derivative for each curve (38.1, 38.8, and 23.1  Pa, 
respectively). At 100% strain, G′ for all clots was roughly equal 
(≈1400–1500 Pa). Comparing G′ between 0.1% and 100% strain, 
hELP-Fb clots stiffened 4.6-fold, while conELP-Fb and HEPES-
Fb clots stiffened 8.8- and 8.4-fold, respectively. Considering 
these results in the context of Fb hierarchical structure, it seems 
likely that by cross-linking protofibrils, hELPs minimize thermal 
fluctuations of unstructured regions of the network in the low 
strain range.[62] Once the clot is sufficiently stretched, the elastic 
response is dominated by stretching of individual fibers, and 
therefore the addition of additional cross-links in the form of 
hELP coacervates no longer plays a role. Previous studies have 
shown that supplemental FXIII increases the elastic modulus 
of Fb clots at low strains within the linear viscoelastic region for 
fibrin, but not in the nonlinear portion of the stress–strain curve, 
similar to what we observed here with addition of hELPs.[54]
2.8. Effect of hELP Coacervates on Plasminolysis
In the body, clots are enzymatically degraded by the protease 
plasmin, which is generated from plasminogen upon activation 
by tissue-plasminogen activator (tPa).[48] The proteolytic activity 
of plasmin is regulated spatiotemporally by binding of tPa and 
plasminogen to exposed cryptic binding sites on Fb clots.[64] 
It has previously been shown that cross-linking by FXIIIa has 
an inhibitory effect on fibrinolysis in vivo.[48] Since hELP coac-
ervates are covalently integrated into Fb clots by FXIIIa, we 
hypothesized that hELPs could extend the lifetime of Fb clots in 
the presence of plasmin. To evaluate this, we performed time-
lapse confocal microscopy.
Fluorescent Fb clots (formed with 1.5 mg mL−1 Fg) containing 
30 × 10−6 m hELP, conELP, or an equivalent volume of HEPES 
were formed in a chambered coverslip, and a solution of plasmin 
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at physiological concentration (10  µg mL−1) was applied to the 
clot front.[47] Images were taken at regular time intervals and ana-
lyzed in order to assess the proportion of clot lysed over time. 
Results indicated large differences in plasminolysis rates between 
hELP and control clots. Typically, HEPES control clots were com-
pletely degraded from the microscope field of view 4 min after 
the application of plasmin, whereas roughly 20% of conELP-Fb 
and 85% of hELP-Fb clot remained (Figure 6). The lysis rate in 
hELP-Fb clots was roughly three times slower than that found in 
conELP-Fb clots, and roughly five times slower than that found 
in HEPES-Fb clots. HELPs do not contain sequences recognized 
by plasmin,[65] therefore the additional nondegradable compo-
nent in the gel inhibited fibrinolysis.
3. Conclusion
We report a novel mechanism for strengthening fibrin clots 
based on FXIIIa-mediated cross-linking and coacervation of 
ELPs. Our new design for hemostatic elastin-like polypeptides 
(hELPs) containing N- and C-terminal repetitive Q- and K-block 
sequences allowed them to be covalently integrated into fibrin 
clots via the natural clotting cascade. This approach does not 
require addition of cross-linking agents or bio-orthogonal func-
tional groups, and occurs through the action of the human 
clotting associated transglutaminase FXIIIa. At physiological 
temperatures above the LCST, hELP coacervates improved 
the mechanical strength of fibrin clots formed under both 
normal and simulated coagulopathic conditions. Stiffening 
was not observed for fibrin networks formed in the presence 
of a control ELP (conELP) having nonreactive mutated FXIIIa-
recognition sequences or for hELP-Fb networks formed at 
temperatures below LCST. This indicated that both covalent 
integration and phase transition of hELPs were necessary to 
impart clot stiffening.
HELPs were found to reduce the flow rate of buffer through 
fibrin clots, thereby improving the sealing properties of these 
materials. The addition of hELPs to Fb networks increased 
kinetic gelation rate following the initiation of clotting, and 
increased their resistance to plasmin degradation. Furthermore, 
hELPs were found to be noncytotoxic (Figure S6, Supporting 
Information). We foresee this mechanism of clot stiffening based 
on coacervation to be applicable in clinical settings for bleeding 
control, as well as in the treatment of other diseases involving 
components of the extracellular matrix or in the context of tissue 
engineering, wherein material stiffness plays an important role.
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Figure 6. Degradation of Fb clots by plasmin. a) Time-lapse confocal images of 1.5 mg mL−1 Fb clots containing 30 × 10−6 m hELP, conELP, or HEPES 
buffer, following exposure of the clot front to 10 µg mL−1 plasmin at 37 °C. Scale bars are 60 µm. b) Quantification of the proportion of clot lysed over 
time for 1.5 mg mL−1 Fb clots containing 30 × 10−6 m hELP, conELP, or HEPES buffer, as determined from confocal images of multiple clots (n = 3).
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